Paclitaxel-loaded polymeric microparticles: Quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 737-744

  Tsai, Max ^a,c   Lu, Ze ^b   Wientjes, M Guillaume ^a,b   Au, Jessie L S ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b Optimum Energy LLC   (United States)

^c Takeda Pharmaceuticals International Inc   (United States)

Author keywords

Controlled release; In vitro in vivo correlation; Intraperitoneal therapy; Paclitaxel; PLGA microparticles

Indexed keywords

CONTROLLED RELEASE; INTRAPERITONEAL; PACLITAXEL; PLGA MICROPARTICLES; VITRO-IN VIVO CORRELATION;

COPOLYMERS; DRUG DELIVERY; MAMMALS; OPTIMIZATION; PATIENT TREATMENT; PHARMACODYNAMICS; TOXICITY; VISCOSITY;

POLYMERS;

CREMOPHOR; DRUG CARRIER; MICROPARTICLE; PACLITAXEL; POLYGLACTIN; UNCLASSIFIED DRUG;

ABDOMINAL SWELLING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; FEMALE; IN VITRO STUDY; INTRAPERITONEAL THERAPY; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEAL CAVITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; THERAPY; VISCOSITY; WEIGHT GAIN; WEIGHT REDUCTION;

AIC; AKAIKE INFORMATION CRITERION; CONTROLLED RELEASE; GA; GLASS TRANSITION TEMPERATURE; GLYCOLIC ACID; HIGH PERFORMANCE LIQUID CHROMATOGRAPH; HPLC; ILS; IN VITRO-IN VIVO CORRELATION; INCREASE IN LIFE SPAN; INHERENT VISCOSITY; INTRAPERITONEAL; INTRAPERITONEAL THERAPY; IP; LA; LACTIC ACID; LARGE MICROPARTICLES WITH MEDIUM RELEASE RATE; LM; MEDIAN SURVIVAL TIME; MICROPARTICLES; MP; MST; PACLITAXEL; PLGA; PLGA MICROPARTICLES; POLY(D,L-LACTIDE-CO-GLYCOLIDE) ACID; SF; SMALL MICROPARTICLES WITH FAST RELEASE RATE; SMALL MICROPARTICLES WITH SLOW RELEASE RATE; SS; TG; VIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, NUDE; PACLITAXEL; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID;

EID: 84887201583     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.09.011     Document Type: Article

References (35)

1. Cancer Facts and Figures 2013 American Cancer Society
2. S. Zimm, S.M. Cleary, W.E. Lucas, R.J. Weiss, M. Markman, P.A. Andrews, M.A. Schiefer, S. Kim, C. Horton, and S.B. Howell Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide Cancer Res. 47 1987 1712 1716 (Pubitemid 17044509)
3. J.D. Nagel, F.J. Varossieau, R. Dubbelman, W.W. Bokkel Huinink, and J.G. McVie Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration Cancer Chemother. Pharmacol. 29 1992 480 484
4. M. Markman, T. Hakes, B. Reichman, W. Hoskins, S. Rubin, W. Jones, L. Almadones, and J.L. Lewis Jr. Intraperitoneal therapy in the management of ovarian carcinoma Yale J. Biol. Med. 62 1989 393 403 (Pubitemid 20005031)
5. D.J. Kerr, and G. Los Pharmacokinetic principles of locoregional chemotherapy Cancer Surv. 17 1993 105 122
6. F. Elferink, W.J. van der Vijgh, I. Klein, W.W. ten Bokkel Huinink, R. Dubbelman, and J.G. McVie Pharmacokinetics of carboplatin after intraperitoneal administration Cancer Chemother. Pharmacol. 21 1988 57 60 (Pubitemid 18050483)
7. J.L. Speyer, J.M. Collins, R.L. Dedrick, M.F. Brennan, A.R. Buckpitt, H. Londer, V.T. DeVita Jr., and C.E. Myers Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally Cancer Res. 40 1980 567 572 (Pubitemid 10174869)
8. M. Markman, E. Rowinsky, T. Hakes, B. Reichman, W. Jones, J.L. Lewis Jr., S. Rubin, J. Curtin, R. Barakat, and M. Phillips Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study J. Clin. Oncol. 10 1992 1485 1491 (Pubitemid 23059933)
9. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. Clarke-Pearson, V.K. Malviya, and B. DuBeshter Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955 (Pubitemid 26428219)
10. V.J. Verwaal, S. van Ruth, E. de Bree, G.W. van Sloothen, H. van Tinteren, H. Boot, and F.A. Zoetmulder Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J. Clin. Oncol. 21 2003 3737 3743 (Pubitemid 46606227)
11. A. Gadducci, F. Carnino, S. Chiara, I. Brunetti, L. Tanganelli, A. Romanini, M. Bruzzone, and P.F. Conte Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest Gynecol. Oncol. 76 2000 157 162 (Pubitemid 30067189)
12. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, S. Wadler, and J. Sickel Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007 (Pubitemid 32176274)
13. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, L.J. Copeland, J.L. Walker, and R.A. Burger Intraperitoneal cisplatin and paclitaxel in ovarian cancer N. Engl. J. Med. 354 2006 34 43 (Pubitemid 43048949)
14. R.F. Ozols, M.A. Bookman, and R.C. Young Intraperitoneal chemotherapy for ovarian cancer N. Engl. J. Med. 354 2006 1641 1643
15. M. Markman, and J.L. Walker Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment J. Clin. Oncol. 24 2006 988 994 (Pubitemid 46638854)
16. Z. Lu, J. Wang, M.G. Wientjes, and J.L. Au Intraperitoneal therapy for peritoneal cancer Future Oncol. 6 2010 1625 1641
17. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 2007 1691 1701 (Pubitemid 47206619)
18. P. Periti, T. Mazzei, and E. Mini Clinical pharmacokinetics of depot leuprorelin Clin. Pharmacokinet. 41 2002 485 504 (Pubitemid 34804161)
19. P. Menei, M.C. Venier, E. Gamelin, J.P. Saint-Andre, G. Hayek, E. Jadaud, D. Fournier, P. Mercier, G. Guy, and J.P. Benoit Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study Cancer 86 1999 325 330 (Pubitemid 29327590)
20. B.H. Woo, K.H. Na, B.A. Dani, G. Jiang, B.C. Thanoo, and P.P. DeLuca In vitro characterization and in vivo testosterone suppression of 6-month release poly(d,l-lactide) leuprolide microspheres Pharm. Res. 19 2002 546 550 (Pubitemid 34408958)
21. E. Piskin Biodegradable polymers as biomaterials J. Biomater. Sci. Polym. Ed. 6 1995 775 795
22. B.D. Ratner, A.S. Hoffman, F.J. Shoen, and J.E. Lemons Biomaterials Science: An Introduction to Materials in Science 1996 Academic Press San Diego
23. V.R. Sinha, and A. Trehan Biodegradable microspheres for protein delivery J. Control. Release 90 2003 261 280 (Pubitemid 36859959)
24. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review Int. J. Pharm. 415 2011 34 52
25. M.O. Omelczuk, and J.W. McGinity The influence of polymer glass transition temperature and molecular weight on drug release from tablets containing poly(dl-lactic acid) Pharm. Res. 9 1992 26 32
26. H.B. Hopfenberg Controlled release from erodible slabs, cylinders, and spheres D.R. Paul, F.W. Harris, Controlled Release Polymeric Formulations 1976 26 32
27. Y. Fu, and W.J. Kao Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems Expert Opin. Drug Deliv. 7 2010 429 444
28. H. Akaike Maximum likelihood identification of Gaussian autoregressive moving average models Biometrika 60 1973 255 265
29. M. Hariharan, and J.C. Price Solvent, emulsifier and drug concentration factors in poly(d,l-lactic acid) microspheres containing hexamethylmelamine J. Microencapsul. 19 2002 95 109 (Pubitemid 34083465)
30. W.M. Obeidat, and J.C. Price Viscosity of polymer solution phase and other factors controlling the dissolution of theophylline microspheres prepared by the emulsion solvent evaporation method J. Microencapsul. 20 2003 57 65 (Pubitemid 36192919)
31. R.T. Liggins, and H.M. Burt Paclitaxel loaded poly(l-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers Int. J. Pharm. 222 2001 19 33 (Pubitemid 32525785)
32. Z. Lu, M. Tsai, D. Lu, J. Wang, M.G. Wientjes, and J.L. Au Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer J. Pharmacol. Exp. Ther. 327 2008 673 682
33. J. Wang, Z. Lu, Y. Gao, M.G. Wientjes, and J.L. Au Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming Nanomedicine (Lond.) 6 2011 1605 1620
34. J.L.S. Au, S.H. Jang, J. Zheng, C.T. Chen, S. Song, L. Hu, and M.G. Wientjes Determinants of drug delivery and transport to solid tumors J. Control. Release 74 2001 31 46 (Pubitemid 32727607)
35. S.H. Jang, M.G. Wientjes, D. Lu, and J.L. Au Drug delivery and transport to solid tumors Pharm. Res. 20 2003 1337 1350 (Pubitemid 37164040)